Payment overview · 2025
General Payments
$2,527.92
189 reported records · 18 companies
Healthcare provider profile · identity verified
David Lawrence Patick, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTINGTON, WV · NPI 1972546273
Verified facts
What the public records show
CMS Open Payments records show David Lawrence Patick, MD received $2,527.92 in general payments during 2025 across 189 reported records.
Novo Nordisk Inc accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Linzess, Mounjaro, Otezla, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $450.59 | 17.8% | 41 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $275.40 | 10.9% | 23 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $229.89 | 9.1% | 16 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $211.46 | 8.4% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $210.06 | 8.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $203.59 | 8.1% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.84 | 6.6% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $167.62 | 6.6% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $166.47 | 6.6% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.74 | 5.7% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.46 | 5.5% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $46.79 | 1.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.31 | 1.2% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $21.48 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.94 | 0.8% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.26 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.62 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.40 | 0.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,527.92 | 189 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $309.27 | 28 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $229.89 | 16 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $211.46 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $192.54 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $191.46 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $189.85 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $164.71 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $152.23 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $149.16 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.46 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $138.23 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $136.94 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $134.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $121.33 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $114.43 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.15 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.94 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.56 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $60.97 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.50 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.50 | 11 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $48.44 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.36 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $31.21 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.57 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $10.35 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.40 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 322 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 156 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 146 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 34 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
322 | 68 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
146 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
322 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1083 | 300 |
| Alprazolam | Alprazolam | 917 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 914 | 232 |
| Lisinopril | Lisinopril | 812 | 214 |
| Metoprolol Succinate | Metoprolol Succinate | 716 | 198 |
| Omeprazole | Omeprazole | 678 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 651 | 196 |
| Simvastatin | Simvastatin | 523 | 137 |
| Metformin Hcl | Metformin Hcl | 472 | 115 |
| Gabapentin | Gabapentin | 461 | 90 |
| Cefdinir | Cefdinir | 435 | 203 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 127 |
| Potassium Chloride | Potassium Chloride | 406 | 107 |
| Furosemide | Furosemide | 366 | 130 |
| Montelukast Sodium | Montelukast Sodium | 332 | 105 |
| Eliquis | Apixaban | 322 | 68 |
| Glimepiride | Glimepiride | 297 | 77 |
| Irbesartan | Irbesartan | 296 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 292 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 87 |
| Torsemide | Torsemide | 268 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 257 | 75 |
| Valsartan | Valsartan | 242 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 72 |
| Losartan Potassium | Losartan Potassium | 235 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 227 | 64 |
| Famotidine | Famotidine | 218 | 56 |
| Meloxicam | Meloxicam | 217 | 55 |
| Metformin Hcl Er | Metformin Hcl | 208 | 66 |
| Sertraline Hcl | Sertraline Hcl | 208 | 60 |
| Tramadol Hcl | Tramadol Hcl | 205 | 33 |
| Trazodone Hcl | Trazodone Hcl | 205 | 61 |
| Ibuprofen | Ibuprofen | 203 | 60 |
| Azithromycin | Azithromycin | 192 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 66 |
| Allopurinol | Allopurinol | 178 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 45 |
| Methylprednisolone | Methylprednisolone | 173 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 46 |
| Atenolol | Atenolol | 169 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 59 |
| Lorazepam | Lorazepam | 157 | 23 |
| Jardiance | Empagliflozin | 156 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 30 |
| Carvedilol | Carvedilol | 148 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 33 |
| Ezetimibe | Ezetimibe | 148 | 37 |
| Ozempic | Semaglutide | 146 | 20 |
| Januvia | Sitagliptin Phosphate | 142 | 35 |
| Baclofen | Baclofen | 140 | 37 |
| Donepezil Hcl | Donepezil Hcl | 138 | 43 |
| Fenofibrate | Fenofibrate | 138 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 136 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 24 |
| Spironolactone | Spironolactone | 122 | 37 |
| Fluconazole | Fluconazole | 121 | 54 |
| Tresiba Flextouch U-200 | Insulin Degludec | 120 | 32 |
| Clonazepam | Clonazepam | 119 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 29 |
| Synthroid | Levothyroxine Sodium | 108 | 27 |
| Temazepam | Temazepam | 107 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 101 | 49 |
| Diazepam | Diazepam | 97 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 96 | 25 |
| Mirtazapine | Mirtazapine | 94 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 26 |
| Mounjaro | Tirzepatide | 90 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 47 |
| Warfarin Sodium | Warfarin Sodium | 88 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 30 |
| Prednisone | Prednisone | 87 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 84 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 79 | 20 |
| Ondansetron Odt | Ondansetron | 78 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 24 |
| Buspirone Hcl | Buspirone Hcl | 77 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 22 |
| Estradiol | Estradiol | 72 | 24 |
| Xarelto | Rivaroxaban | 69 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 32 |
| Finasteride | Finasteride | 67 | 19 |
| Celecoxib | Celecoxib | 66 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 13 |
| Felodipine Er | Felodipine | 58 | 15 |
| Acyclovir | Acyclovir | 57 | 11 |
| Labetalol Hcl | Labetalol Hcl | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 16 |
| Telmisartan | Telmisartan | 56 | 19 |
| Nystatin | Nystatin | 55 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 18 |
| Primidone | Primidone | 54 | 14 |
| Promethazine Hcl | Promethazine Hcl | 52 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 16 |
| Valacyclovir | Valacyclovir Hcl | 51 | 19 |
| Ketoconazole | Ketoconazole | 48 | 24 |
| Cefuroxime | Cefuroxime Axetil | 47 | 26 |
| Levofloxacin | Levofloxacin | 47 | 30 |
| Methocarbamol | Methocarbamol | 47 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 14 |
| Bupropion Xl | Bupropion Hcl | 45 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 45 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 17 |
| Lansoprazole | Lansoprazole | 44 | 14 |
| Meclizine Hcl | Meclizine Hcl | 44 | 20 |
| Mupirocin | Mupirocin | 44 | 16 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 43 | 15 |
| Amoxicillin | Amoxicillin | 42 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 42 | 15 |
| Klor-Con M20 | Potassium Chloride | 42 | 18 |
| Levemir Flexpen | Insulin Detemir | 41 | 12 |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Nabumetone | Nabumetone | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | 19 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 38 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Levetiracetam | Levetiracetam | 36 | 12 |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | 11 |
| Linzess | Linaclotide | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | 11 |
| Metronidazole | Metronidazole | 25 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Lactulose | Lactulose | 24 | 15 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Dexamethasone | Dexamethasone | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Nadolol | Nadolol | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Fluocinonide | Fluocinonide | 17 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Sulindac | Sulindac | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 14 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,527.92 · 189 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, CAPVAXIVE, CRYSVITA, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FUROSCIX, GARDASIL 9, GLASSIA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TEPEZZA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XHANCE, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error